Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study

<div>Kaplan–Meier plots of hospitalization for acute pancreatitis in (a) all patients, (b) patients with underlying cardiovascular disease, and (c) patients without underlying cardiovascular disease. DPP-4i: dipeptidyl-peptidase IV inhibitor; <i>N</i>: number of patients; SU: sulfonylurea; y: year(s).</div>

Journal of Diabetes Research

fig2

Figure 2

Figure 2: Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study 